Familial Alzheimer’s disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.